
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Dr. Pedro Bastos shares how real-world evidence for approved biologics is essential to inform the treatment of PN across diverse comorbid patient populations, including insights into rapid itch relief, progressive skin clearance, long-term outcomes, and safety.
Join Drs. Sarina Elmariah and Pedro Bastos to explore the full systemic burden of prurigo nodularis, looking beyond the nodules to discover how real-world evidence for approved biologics can inform treatment decisions and long-term care across diverse patient populations.
Drs. Sarina Elmariah and Pedro Bastos led an engaging ADVENT Industry Hub at EADV 2026 in Vienna, Austria, exploring the full systemic burden of prurigo nodularis (PN) beyond its visible nodules. The session highlighted how real-world evidence for approved biologics can inform treatment decisions and support long-term disease management across diverse patient populations.

Explore the dynamic advancements in COPD biologic therapies. Prof. Klaus Rabe, MD, Prof. Claus Vogelmeier, MD, and Prof. Wisia Wedzicha, MD, present and analyze the latest clinical data, offering key insights into current and emerging therapeutic strategies for managing COPD.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.
Fiona Lovegrove, MD, PhD, reviews Canadian consensus recommendations for the diagnosis and management of bullous pemphigoid (BP).